safety Moderate

Tesamorelin Safety: Label Warnings and Trial Limits

Tesamorelin has trial data for HIV-associated lipodystrophy, but its label includes glucose, IGF-1, malignancy and other warnings. Approval does not establish safety for every use.

PepCodex Research Team
6 min read
#tesamorelin #egrifta #safety #fda-approved #ghrh

What the safety evidence covers

Tesamorelin trials studied defined populations and follow-up periods. The pooled pivotal report included a 26-week placebo-controlled phase and a 26-week extension; it is not proof of lifelong safety or safety in healthy users. Evidence grade: moderate for the characterized trial safety profile; long-term risks remain uncertain. (Pooled report)

Main label warnings

The Egrifta WR label addresses elevated IGF-1, glucose intolerance or diabetes, fluid retention with joint symptoms, hypersensitivity and injection-site reactions. Its malignancy warning relates to the growth hormone pathway and individual history. Long-term cardiovascular safety has not been established. (FDA label)

The label’s critical-illness precaution draws on mortality observed with pharmacologic growth hormone; it should not be described as a demonstrated tesamorelin mortality rate. The label also identifies potential interactions with CYP450-metabolized medicines and glucocorticoid replacement. (Prescribing information)

Contraindications and formulations

Listed contraindications include active malignancy, specified disruption of the hypothalamic-pituitary axis, pregnancy, and hypersensitivity to tesamorelin or formulation ingredients. Egrifta WR and SV are not substitutable; formulation-specific labeling matters. (FDA label)

Why there is no universal side-effect percentage

Adverse-event rates depend on the event definition, study population and duration. The label cautions against direct comparisons across different drug trials. This page therefore avoids combining unrelated event categories into approximate frequency ranges. The dedicated safety page and dossier link to the source evidence. (Current label)

Educational information, not individual risk assessment or advice to start, stop or combine treatments.

Sources & Citations

Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.